Ipca Laboratories gains despite reporting 6% fall in Q2 consolidated net profit
Follow us Now on Telegram ! Get daily 10 - 12 important updates on Business, Finance and Investment. Join our Telegram Channel
Ipca Laboratories is currently trading at Rs. 1053.25, up by 20.35 points or 1.97% from its previous closing of Rs. 1032.90 on the BSE.
The scrip opened at Rs. 1032.90 and has touched a high and low of Rs. 1060.00 and Rs. 1026.00 respectively. So far 17442 shares were traded on the counter.
The BSE group 'A' stock of face value Rs. 1 has touched a 52 week high of Rs. 1065.20 on 09-Nov-2023 and a 52 week low of Rs. 670.00 on 22-May-2023.
Last one week high and low of the scrip stood at Rs. 1065.20 and Rs. 984.70 respectively. The current market cap of the company is Rs. 26740.42 crore.
The promoters holding in the company stood at 46.29%, while Institutions and Non-Institutions held 44.91% and 8.81% respectively.
Ipca Laboratories has reported results for second quarter ended September 30, 2023 (Q2FY24).
The company has reported 2.11% fall in its net profit at Rs 162.13 crore for the quarter under review as compared to Rs 165.63 crore for the same quarter in the previous year. However, total income of the company increased by 11.02% at Rs 1,698.81 crore for Q2FY24 as compared to Rs 1,530.16 crore for the corresponding quarter previous year.
On consolidated basis, the company has reported 6.39% fall in its net profit at Rs 137.44 crore for Q2FY24 as compared to Rs 146.82 crore for the same quarter in the previous year. However, total income of the company increased by 26.59% at Rs 2,072.51 crore for Q2FY24 as compared to Rs 1,637.18 crore for the corresponding quarter previous year.
